A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The Food and Drug Administration late Thursday approved a new non-opioid pain pill from Vertex Pharmaceuticals, one of the most closely-watched drugs in all of biotech. Now comes the real test ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepared for tomorrow’s Federal Reserve announcement.

New Orleans-based investment network Gulf South Angels is investing in non-opioid pain drug startup South Rampart Pharma as ...